Ozempic’s maker is in trouble. Tablets may be the answer
Just a few years ago, Novo Nordisk was the darling of the healthcare industry. Now it is teetering.
Just a few years ago, Novo Nordisk was the darling of the healthcare industry. Now it is teetering.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
Just a few years ago, Novo Nordisk was the darling of the healthcare industry. Now it is teetering.